Clover Health Projects First-Ever GAAP Net Income Profitability in 2026 Amidst Strong Growth
CLOV is trading near its 52-week low of $1.94 (14% above the low).
Summary
Clover Health reported strong Q4 and full year 2025 results, including positive Adjusted EBITDA, and issued optimistic 2026 guidance projecting its first-ever full year of GAAP Net Income profitability.
Key Events · Earnings and Guidance · CLOV
-
Projects First-Ever GAAP Net Income Profitability in 2026
Clover Health anticipates achieving GAAP Net Income between $0 million and $20 million for the full year 2026, marking a significant milestone for the company.
-
Strong 2026 Revenue and Membership Growth Guidance
The company projects total revenues between $2.81 billion and $2.92 billion for 2026, representing 49% year-over-year growth at the midpoint, alongside average Medicare Advantage membership of 154,000 - 158,000, a 46% increase.
-
Achieved Full Year 2025 Adjusted EBITDA Profitability
For the full year 2025, Clover Health reported Adjusted EBITDA of $22 million and Adjusted Net Income of $20 million, demonstrating financial resilience despite a GAAP Net loss of $86 million.
-
Significant 2025 Membership and Revenue Growth
Full year 2025 Medicare Advantage membership grew 38% year-over-year to 113,803, with total revenues increasing 40% to $1.9 billion.
Analysis · CLOV · Finance
This filing is highly significant as Clover Health has provided detailed financial results for Q4 and full year 2025, alongside robust guidance for 2026. The most critical update is the projection of achieving GAAP Net Income profitability for the full year 2026, a first for the company. This solidifies the anticipation of profitability previously announced on January 14, 2026, by providing concrete financial ranges. The strong growth in Medicare Advantage membership and total revenues, both in 2025 and projected for 2026, further validates the company's business model and operational leverage. This shift to profitability, coupled with continued expansion, represents a material positive change in the company's financial trajectory and investment thesis.
At the time of this filing, CLOV was trading at $2.22 on NASDAQ in the Finance sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.94 to $4.52. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.